دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial
Hyon K. Choi,Tuhina Neogi,Lisa K. Stamp,Robert Terkeltaub,Nicola Dalbeth
doi : 10.1002/art.41638
Volume 73, Issue 5 p. 721-724
Combining Data Sets as Well as Therapies Shows Improved Outcome in Connective Tissue Disease–Associated Pulmonary Hypertension
Christopher P. Denton,Julia Spierings
doi : 10.1002/art.41670
Volume 73, Issue 5 p. 725-727
Could Compensatory Autoantibody Production Affect Rheumatoid Arthritis Etiopathogenesis?
Gregg J. Silverman
doi : 10.1002/art.41673
Volume 73, Issue 5 p. 728-730
Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19
Joht Singh Chandan,Dawit Tefra Zemedikun,Rasiah Thayakaran,Nathan Byne,Samir Dhalla,Dionisio Acosta-Mena,Krishna M. Gokhale,Tom Thomas,Christopher Sainsbury,Anuradhaa Subramanian,Jennifer Cooper,Astha Anand,Kelvin O. Okoth,Jingya Wang,Nicola J. Adderley,Thomas Taverner,Alastair K. Denniston,Janet Lord,G. Neil Thomas,Christopher D. Buckley,Karim Raza,Neeraj Bhala,Krishnarajah Nirantharakumar,Shamil Haroon
doi : 10.1002/art.41593
Volume 73, Issue 5 p. 731-739
To identify whether active use of nonsteroidal antiinflammatory drugs (NSAIDs) increases susceptibility to developing suspected or confirmed coronavirus disease 2019 (COVID-19) compared to the use of other common analgesics.
Expansion of Alternative Autoantibodies Does Not Follow the Evolution of Anti–Citrullinated Protein Antibodies in Preclinical Rheumatoid Arthritis: An Analysis in At-Risk First Degree Relatives
Vidyanand Anaparti,Irene Smolik,Xiaobo Meng,Liam O’Neil,Mackenzie A. Jantz,Marvin J. Fritzler,Hani El-Gabalawy
doi : 10.1002/art.41675
Volume 73, Issue 5 p. 740-749
Co-occurrence of autoantibodies specific for ≥1 autoimmune disease is widely prevalent in rheumatoid arthritis (RA) patients. To understand the prevalence of polyautoimmunity in preclinical RA, we performed a comprehensive autoantibody assessment in a First Nations cohort of at-risk first-degree relatives (FDR) of RA patients, a subset of whom subsequently developed RA (progressors).
Lifetime Risks, Life Expectancy, and Health Care Expenditures for Rheumatoid Arthritis: A Nationwide Cohort Followed Up From 2003 to 2016
Ying-Ming Chiu,Yi-Peng Lu,Joung-Liang Lan,Der-Yuan Chen,Jung-Der Wang
doi : 10.1002/art.41597
Volume 73, Issue 5 p. 750-758
This study was undertaken to estimate the cumulative incidence rate of rheumatoid arthritis (RA) in the Taiwanese population ages 16–84 years, and life expectancy, loss of life expectancy, and lifetime health care expenditures for incident RA in Taiwan after 2003, when biologics began to be prescribed.
Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
Jeffrey R. Curtis,Paul Emery,Elaine Karis,Boulos Haraoui,Vivian Bykerk,Priscilla K. Yen,Greg Kricorian,James B. Chung
doi : 10.1002/art.41589
Volume 73, Issue 5 p. 759-768
Patients with rheumatoid arthritis (RA) in whom remission is achieved following combination therapy with methotrexate plus etanercept face an ongoing medication burden. This study was undertaken to investigate whether sustained remission achieved on combination therapy can be maintained with either methotrexate or etanercept monotherapy, as assessed following discontinuation of one or the other medication from the combination.
Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin-10 in Murine Models
Eiji Yuba,Erica Budina,Kiyomitsu Katsumata,Ako Ishihara,Aslan Mansurov,Aaron T. Alpar,Elyse A. Watkins,Peyman Hosseinchi,Joseph W. Reda,Abigail L. Lauterbach,Mindy Nguyen,Ani Solanki,Takahiro Kageyama,Melody A. Swartz,Jun Ishihara,Jeffrey A. Hubbell
doi : 10.1002/art.41585
Volume 73, Issue 5 p. 769-778
Rheumatoid arthritis (RA) is a major autoimmune disease that causes synovitis and joint damage. Although clinical trials have been performed using interleukin-10 (IL-10), an antiinflammatory cytokine, as a potential treatment of RA, the therapeutic effects of IL-10 have been limited, potentially due to insufficient residence in lymphoid organs, where antigen recognition primarily occurs. This study was undertaken to engineer an IL-10–serum albumin (SA) fusion protein and evaluate its effects in 2 murine models of RA.
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis
Mark Yates,Amanda Mootoo,Maryam Adas,Katie Bechman,Sanketh Rampes,Vishit Patel,Sumera Qureshi,Andrew P. Cope,Sam Norton,James B. Galloway
doi : 10.1002/art.41580
Volume 73, Issue 5 p. 779-788
JAK inhibitor therapies are effective treatment options for immune-mediated inflammatory diseases (IMIDs), but their use has been limited by venous thromboembolism (VTE) risk warnings from licensing authorities. We undertook this study to evaluate the VTE risk of JAK inhibitors in patients with IMIDs.
RNA Sequencing Reveals Interacting Key Determinants of Osteoarthritis Acting in Subchondral Bone and Articular Cartilage: Identification of IL11 and CHADL as Attractive Treatment Targets
Margo Tuerlings,Marcella van Hoolwerff,Evelyn Houtman,Eka H. E. D. Suchiman,Nico Lakenberg,Hailiang Mei,Enrike H. M. J. van der Linden,Rob R. G. H. H. Nelissen,Yolande Y. F. M. Ramos,Rodrigo Coutinho de Almeida,Ingrid Meulenbelt
doi : 10.1002/art.41600
Volume 73, Issue 5 p. 789-799
To identify key determinants of the interactive pathophysiologic processes in subchondral bone and cartilage in osteoarthritis (OA).
Incorrect Academic Degree and/or Affiliation Information for Two Authors in the Article by Rodr?guez-Carrio et al (Arthritis Rheumatol, March 2021)
doi : 10.1002/art.41755
Volume 73, Issue 5 p. 799-799
Error in Figure 2B of the Article by Kolasinski et al (Arthritis Rheumatol, February 2020)
doi : 10.1002/art.41761
Volume 73, Issue 5 p. 799-799
Which Magnetic Resonance Imaging Lesions in the Sacroiliac Joints Are Most Relevant for Diagnosing Axial Spondyloarthritis? A Prospective Study Comparing Rheumatologists’ Evaluations With Radiologists’ Findings
X. Baraliakos,A. Ghadir,M. Fruth,U. Kiltz,I. Redeker,J. Braun
doi : 10.1002/art.41595
Volume 73, Issue 5 p. 800-805
Pathologic sacroiliac (SI) joint changes on magnetic resonance imaging (MRI) are important for the classification of axial spondyloarthritis (SpA). In daily practice, radiologists play a major role in interpreting imaging findings. This study was undertaken to evaluate the impact of MRI SI joint findings on the identification of axial SpA by radiologists, in comparison to diagnosis by rheumatologists.
Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six-Month Results of a Placebo-Controlled Trial
Tamara Rusman,Mignon A. C. van der Weijden,Michael T. Nurmohamed,Robert B. M. Landew?©,Janneke J. H. de Winter,Bouke J. H. Boden,Pierre M. Bet,Carmella M. A. van der Bijl,Conny van der Laken,Irene E. van der Horst-Bruinsma
doi : 10.1002/art.41607
Volume 73, Issue 5 p. 806-815
To investigate the efficacy of 16-week treatment with etanercept (ETN) in patients with suspected nonradiographic axial spondyloarthritis (SpA).
Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study
W. Winn Chatham,Richard Furie,Amit Saxena,Philip Brohawn,Erik Schwetje,Gabriel Abreu,Raj Tummala
doi : 10.1002/art.41598
Volume 73, Issue 5 p. 816-825
To investigate long-term safety and tolerability of anifrolumab, a human monoclonal antibody to the type I interferon (IFN) receptor subunit 1, in patients with moderate-to-severe systemic lupus erythematosus (SLE).
The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model
Anthony D. Marinov,Haowei Wang,Sheldon I. Bastacky,Erwin van Puijenbroek,Thomas Schindler,Dario Speziale,Mario Perro,Christian Klein,Kevin M. Nickerson,Mark J. Shlomchik
doi : 10.1002/art.41608
Volume 73, Issue 5 p. 826-836
Depleting pathogenic B cells could treat systemic lupus erythematosus (SLE). However, depleting B cells in an inflammatory setting such as lupus is difficult. This study was undertaken to investigate whether a type II anti-CD20 monoclonal antibody (mAb) with a different mechanism of action, obinutuzumab (GA101), is more effective than a type I anti-CD20 mAb, rituximab (RTX), in B cell depletion in lupus, and whether efficient B cell depletion results in amelioration of disease.
Long-Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries
Dinesh Khanna,Carol Zhao,Rajan Saggar,Stephen C. Mathai,Lorinda Chung,J. Gerry Coghlan,Mehul Shah,John Hartney,Vallerie McLaughlin
doi : 10.1002/art.41669
Volume 73, Issue 5 p. 837-847
Data on the magnitude of benefit of modern therapies for pulmonary arterial hypertension (PAH) in connective tissue disease (CTD)–associated PAH are limited. In this study, we performed meta-analyses of randomized, controlled trials (RCTs) and registries to quantify the benefit of these modern therapies in patients with CTD-PAH.
Eccentric Resistance Training Ameliorates Muscle Weakness in a Mouse Model of Idiopathic Inflammatory Myopathies
Koichi Himori,Yuki Ashida,Daisuke Tatebayashi,Masami Abe,Yuki Saito,Takako Chikenji,H?¥kan Westerblad,Daniel C. Andersson,Takashi Yamada
doi : 10.1002/art.41594
Volume 73, Issue 5 p. 848-857
High-force eccentric contractions (ECCs) have traditionally been excluded from rehabilitation programs that include patients with idiopathic inflammatory myopathies (IIMs) due to unverified fear of causing muscle damage and inflammation. In an IIM animal model that used mice with experimental autoimmune myositis (EAM), we undertook this study to investigate whether ECC training can safely and effectively be used to counteract muscle weakness in IIM.
Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients
Julie J. Paik,Livia Casciola-Rosen,Joseph Yusup Shin,Jemima Albayda,Eleni Tiniakou,Doris G. Leung,Laura Gutierrez-Alamillo,Jamie Perin,Liliana Florea,Corina Antonescu,Sherry G. Leung,Grazyna Purwin,Andrew Koenig,Lisa Christopher-Stine
doi : 10.1002/art.41602
Volume 73, Issue 5 p. 858-865
This open-label 12-week study was conducted to evaluate the efficacy and safety of tofacitinib, a JAK inhibitor, in treatment-refractory active dermatomyositis (DM).
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors
Jeffrey Aldrich,Xerxes Pundole,Sudhakar Tummala,Nicolas Palaskas,Clark R. Andersen,Mahran Shoukier,Noha Abdel-Wahab,Anita Deswal,Maria E. Suarez-Almazor
doi : 10.1002/art.41604
Volume 73, Issue 5 p. 866-874
To estimate the incidence of immune checkpoint inhibitor–related myositis (ICI-myositis) in cancer patients receiving ICIs, and to report associated clinical manifestations, patterns of care, and outcomes.
Synovial Fluid Neutrophils From Patients With Juvenile Idiopathic Arthritis Display a Hyperactivated Phenotype
Mieke Metzemaekers,Bert Malengier-Devlies,Karen Yu,Sofie Vandendriessche,Jonas Yserbyt,Patrick Matthys,Lien De Somer,Carine Wouters,Paul Proost
doi : 10.1002/art.41605
Volume 73, Issue 5 p. 875-884
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood. The predominant subtypes, oligoarticular and polyarticular JIA, are traditionally considered to be autoimmune diseases with a central role for T cells and autoantibodies. Mounting evidence suggests an important role for neutrophils in JIA pathogenesis. We undertook this study to investigate the phenotypic features of neutrophils present in the blood and inflamed joints of patients.
Amelioration of Murine Macrophage Activation Syndrome by Monomethyl Fumarate in Both a Heme Oxygenase 1–Dependent and Heme Oxygenase 1–Independent Manner
Chhanda Biswas,Niansheng Chu,Thomas N. Burn,Portia A. Kreiger,Edward M. Behrens
doi : 10.1002/art.41591
Volume 73, Issue 5 p. 885-895
Macrophage activation syndrome (MAS) is characterized by increased serum levels of ferritin and heme oxygenase 1 (HO-1), and yet no known function is ascribed to these molecules in MAS. Because HO-1 is antiinflammatory, we hypothesized that pharmacologic activation of HO-1 could ameliorate MAS disease activity. Dimethyl fumarate (DMF), a treatment approved by the US Food and Drug Administration for multiple sclerosis, activates HO-1. Monomethyl fumarate (MMF) is the active metabolite of DMF. We therefore evaluated whether MMF could elicit HO-1–dependent therapeutic improvements in a murine model of MAS.
Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVID-19 in New Zealand
Eamon Duffy,Nicola Arroll,Richard Beasley,Thomas Hills
doi : 10.1002/art.41643
Volume 73, Issue 5 p. 896-897
Antiphospholipid Autoantibodies and Thrombosis in Patients With COVID-19: Comment on the Article by Bertin et al
T. Frapard,S. Hue,C. Rial,N. de Prost,A. Mekontso Dessap
doi : 10.1002/art.41634
Volume 73, Issue 5 p. 897-899
Reply
Daniel Bertin,Alexandre Brodovitch,Abdelouahab Beziane,Jean Louis Mege,Xavier Heim,Nathalie Bardin
doi : 10.1002/art.41633
Volume 73, Issue 5 p. 899-900
The Importance of Establishing a Suitable Study Population in Osteoarthritis Studies: Comment on the Article by MacFarlane et al
Duygu Tecer,Muhammet Cinar,Sedat Yilmaz
doi : 10.1002/art.41646
Volume 73, Issue 5 p. 900-901
Reply
Lindsey A. MacFarlane,I-Min Lee,Jeffrey N. Katz,JoAnn E. Manson,Karen H. Costenbader
doi : 10.1002/art.41642
Volume 73, Issue 5 p. 901-902
An Unusual Presentation of Erosive Gout
Fadi Kharouf,Yusef Azraq,Yaakov Applbaum,Hagit Peleg
doi : 10.1002/art.41641
Volume 73, Issue 5 p. 902-902
